Skip to main content
Erschienen in: Clinical Pharmacokinetics 10/2018

23.02.2018 | Original Research Article

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis

verfasst von: Insa Winzenborg, Ahmed Nader, Akshanth R. Polepally, Mohan Liu, Jacob Degner, Cheri E. Klein, Nael M. Mostafa, Peter Noertersheuser, Juki Ng

Erschienen in: Clinical Pharmacokinetics | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Elagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to uterine fibroids. The pharmacokinetics of elagolix have been well-characterized in phase I studies; however, elagolix population pharmacokinetics have not been previously reported. Therefore, a robust model was developed to describe elagolix population pharmacokinetics and to evaluate factors affecting elagolix pharmacokinetic parameters.

Methods

The data from nine clinical studies (a total of 1624 women) were included in the analysis: five phase I studies in healthy, premenopausal women and four phase III studies in premenopausal women with endometriosis.

Results

Elagolix population pharmacokinetics were best described by a two-compartment model with a lag time in absorption. Of the 15 covariates tested for effect on elagolix apparent clearance (CL/F) and/or volume of distribution only one covariate, organic anion transporting polypeptide (OATP) 1B1 genotype status, had a statistically significant, but not clinically meaningful, effect on elagolix CL/F.

Conclusion

Elagolix pharmacokinetics were not affected by patient demographics and were similar between healthy women and women with endometriosis.
Clinical Trial Registration Numbers NCT01403038, NCT01620528, NCT01760954, NCT01931670, NCT02143713.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20(10):2698–704.CrossRefPubMed Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20(10):2698–704.CrossRefPubMed
2.
Zurück zum Zitat Viganò P, Parazzini F, Somigliana E, Vercellini P. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol. 2004;18(2):177–200.CrossRefPubMed Viganò P, Parazzini F, Somigliana E, Vercellini P. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol. 2004;18(2):177–200.CrossRefPubMed
3.
Zurück zum Zitat Facchin F, Barbara G, Saita E, et al. Impact of endometriosis on quality of life and mental health: pelvic pain makes the difference. J Psychosom Obstet Gynaecol. 2015;36(4):135–41.CrossRefPubMed Facchin F, Barbara G, Saita E, et al. Impact of endometriosis on quality of life and mental health: pelvic pain makes the difference. J Psychosom Obstet Gynaecol. 2015;36(4):135–41.CrossRefPubMed
4.
Zurück zum Zitat Struthers RS, Chen T, Campbell B, et al. Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902). J Clin Endocrinol Metab. 2006;91(10):3903–7.CrossRefPubMed Struthers RS, Chen T, Campbell B, et al. Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902). J Clin Endocrinol Metab. 2006;91(10):3903–7.CrossRefPubMed
5.
Zurück zum Zitat Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94(2):545–51.CrossRefPubMed Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94(2):545–51.CrossRefPubMed
6.
Zurück zum Zitat Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–91.CrossRefPubMed Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–91.CrossRefPubMed
7.
Zurück zum Zitat Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014;21(11):1341–51.CrossRefPubMedPubMedCentral Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014;21(11):1341–51.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40.CrossRefPubMed Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40.CrossRefPubMed
9.
Zurück zum Zitat Surrey E, Taylor HS, Giudice LC, et al. Long-term safety and efficacy of elagolix treatment in women with endometriosis-associated pain: primary results from two phase 3 extension studies [abstract no. O-233]. Fertil Steril. 2017;108(3 Suppl):e95–6.CrossRef Surrey E, Taylor HS, Giudice LC, et al. Long-term safety and efficacy of elagolix treatment in women with endometriosis-associated pain: primary results from two phase 3 extension studies [abstract no. O-233]. Fertil Steril. 2017;108(3 Suppl):e95–6.CrossRef
10.
Zurück zum Zitat Archer D, Ng J, Chiu Y-L, Klein C, Chwalisz K. Dose-dependent suppression of ovulation and ovarian activity by elagolix in healthy premenopausal women. Society for Reproductive Investigation (SRI) 64th annual meeting, 15–18 Mar 2017, Orlando. Archer D, Ng J, Chiu Y-L, Klein C, Chwalisz K. Dose-dependent suppression of ovulation and ovarian activity by elagolix in healthy premenopausal women. Society for Reproductive Investigation (SRI) 64th annual meeting, 15–18 Mar 2017, Orlando.
11.
Zurück zum Zitat Ng J, Chiu Y-L, Chwalisz K, Klein C. Effects of elagolix, an oral gonadotropin-releasing hormone (GnRH), on gonadotropins and ovarian sex hormones in healthy premenopausal women [poster no. PS02-003]. World Congress on Endometriosis (WCE), 17–20 May 2017, Vancouver. Ng J, Chiu Y-L, Chwalisz K, Klein C. Effects of elagolix, an oral gonadotropin-releasing hormone (GnRH), on gonadotropins and ovarian sex hormones in healthy premenopausal women [poster no. PS02-003]. World Congress on Endometriosis (WCE), 17–20 May 2017, Vancouver.
12.
Zurück zum Zitat Ng J, Archer D, Chiu Y-L, Klein C, Chwalisz K. Effects of elagolix, an oral gonadotropin-releasing hormone (GnRH), on ovulation, ovarian activity, and ovarian reserve in healthy premenopausal women [poster no. PS02-004]. World Congress on Endometriosis (WCE), 17–20 May 2017, Vancouver. Ng J, Archer D, Chiu Y-L, Klein C, Chwalisz K. Effects of elagolix, an oral gonadotropin-releasing hormone (GnRH), on ovulation, ovarian activity, and ovarian reserve in healthy premenopausal women [poster no. PS02-004]. World Congress on Endometriosis (WCE), 17–20 May 2017, Vancouver.
13.
Zurück zum Zitat Chen C, Wu D, Guo Z, et al. Discovery of sodium r-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2h-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008;51(23):7478–85.CrossRefPubMed Chen C, Wu D, Guo Z, et al. Discovery of sodium r-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2h-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008;51(23):7478–85.CrossRefPubMed
14.
Zurück zum Zitat Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447(5):653–65.CrossRefPubMed Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447(5):653–65.CrossRefPubMed
15.
Zurück zum Zitat Ng J, Salem AH, Carter D, Williams LA, Klein CE. Effects of the coadministration of single and multiple doses of rifampin on the pharmacokinetics and safety of elagolix in healthy premenopausal females [poster no. PI-089]. American Society for Clinical Pharmacology and Therapeutics (ASCPT), 8–12 Mar 2016, San Diego. Ng J, Salem AH, Carter D, Williams LA, Klein CE. Effects of the coadministration of single and multiple doses of rifampin on the pharmacokinetics and safety of elagolix in healthy premenopausal females [poster no. PI-089]. American Society for Clinical Pharmacology and Therapeutics (ASCPT), 8–12 Mar 2016, San Diego.
16.
Zurück zum Zitat Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.CrossRefPubMedPubMedCentral Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.CrossRefPubMedPubMedCentral
Metadaten
Titel
Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis
verfasst von
Insa Winzenborg
Ahmed Nader
Akshanth R. Polepally
Mohan Liu
Jacob Degner
Cheri E. Klein
Nael M. Mostafa
Peter Noertersheuser
Juki Ng
Publikationsdatum
23.02.2018
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 10/2018
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-018-0629-6

Weitere Artikel der Ausgabe 10/2018

Clinical Pharmacokinetics 10/2018 Zur Ausgabe